HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bing Xia Selected Research

LC capilliposide

1/2017Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bing Xia Research Topics

Disease

71Neoplasms (Cancer)
10/2022 - 11/2005
27Ulcerative Colitis
02/2016 - 04/2004
19Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 01/2016
18Colitis
03/2022 - 03/2004
15Inflammation (Inflammations)
03/2022 - 03/2004
15Breast Neoplasms (Breast Cancer)
12/2021 - 06/2006
14Infections
08/2020 - 12/2002
14Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2016 - 03/2007
12Lung Neoplasms (Lung Cancer)
02/2021 - 09/2012
11Crohn Disease (Crohn's Disease)
03/2015 - 04/2004
10Neoplasm Metastasis (Metastasis)
03/2022 - 02/2011
9Stomach Neoplasms (Stomach Cancer)
01/2016 - 02/2005
8Ovarian Neoplasms (Ovarian Cancer)
09/2020 - 08/2002
7Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/2020 - 05/2011
7Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2018 - 05/2012
5Carcinogenesis
01/2022 - 02/2007
5Hypoxia (Hypoxemia)
08/2020 - 06/2014
5Nasopharyngeal Carcinoma
12/2016 - 07/2006
5Virus Diseases (Viral Diseases)
08/2015 - 01/2013
5Gastritis
02/2014 - 02/2005
4Genomic Instability
01/2020 - 10/2017
4Hypersensitivity (Allergy)
08/2014 - 02/2007
4Necrosis
11/2011 - 03/2006
4Peptic Ulcer (Peptic Ulcers)
08/2009 - 02/2005
4Muscular Dystrophies (Muscular Dystrophy)
02/2004 - 04/2002
3Body Weight (Weight, Body)
11/2021 - 01/2013
3Carcinoma (Carcinomatosis)
10/2021 - 06/2015
3Disease Progression
01/2021 - 01/2020
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 01/2015
3Salmonella Infections (Salmonellosis)
08/2020 - 05/2019
3Fibrosis (Cirrhosis)
01/2019 - 03/2015
3Multiple Myeloma
12/2018 - 10/2014
3Wounds and Injuries (Trauma)
09/2016 - 01/2012
3Colorectal Neoplasms (Colorectal Cancer)
01/2012 - 02/2010
3Hyperhomocysteinemia
01/2012 - 05/2007
3Fanconi Anemia (Fanconi's Anemia)
09/2009 - 02/2007
3Adenocarcinoma
02/2007 - 05/2004
2Bites and Stings (Sting)
01/2022 - 01/2022
2Neuroinflammatory Diseases
01/2022 - 04/2020

Drug/Important Bio-Agent (IBA)

41Proteins (Proteins, Gene)FDA Link
04/2022 - 04/2002
21DNA (Deoxyribonucleic Acid)IBA
10/2022 - 05/2007
19Messenger RNA (mRNA)IBA
12/2019 - 03/2006
9Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2019 - 05/2004
8Tyrosine Kinase InhibitorsIBA
05/2021 - 01/2016
8CytokinesIBA
01/2021 - 02/2010
8micaIBA
06/2012 - 10/2005
7SiliconIBA
03/2022 - 08/2014
7Biomarkers (Surrogate Marker)IBA
01/2022 - 04/2011
7ErbB Receptors (EGF Receptor)IBA
05/2021 - 01/2016
5Small Interfering RNA (siRNA)IBA
04/2022 - 03/2009
5LigandsIBA
02/2021 - 04/2011
5AntibodiesIBA
01/2016 - 03/2003
5AntigensIBA
09/2015 - 03/2003
5Folic Acid (Vitamin M)FDA LinkGeneric
09/2015 - 05/2007
5Interleukin-10 (Interleukin 10)IBA
01/2014 - 07/2009
5Peroxidase (Myeloperoxidase)IBA
01/2013 - 03/2006
41,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
09/2022 - 01/2013
4Cisplatin (Platino)FDA LinkGeneric
12/2021 - 09/2014
4Epidermal Growth Factor (EGF)IBA
02/2021 - 10/2011
4RNA (Ribonucleic Acid)IBA
01/2021 - 10/2014
4Anti-Bacterial Agents (Antibiotics)IBA
02/2020 - 10/2018
4Adenosine (Adenocard)FDA LinkGeneric
01/2019 - 03/2015
4Therapeutic UsesIBA
12/2018 - 03/2006
4Biological ProductsIBA
01/2016 - 06/2006
4Sulfonic AcidsIBA
01/2014 - 03/2006
4AcidsIBA
02/2013 - 03/2004
4HomocysteineIBA
01/2012 - 05/2007
4Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric
11/2011 - 05/2007
4Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA
08/2010 - 05/2007
3Poly(ADP-ribose) Polymerase InhibitorsIBA
09/2022 - 11/2017
3InterferonsIBA
01/2022 - 12/2012
3MicroRNAs (MicroRNA)IBA
10/2021 - 10/2015
3Reactive Oxygen Species (Oxygen Radicals)IBA
04/2021 - 01/2021
3UbiquitinIBA
01/2020 - 09/2017
3olaparibIBA
01/2020 - 11/2017
3Pharmaceutical PreparationsIBA
01/2020 - 08/2014
3beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA
01/2019 - 03/2015
3Caspase 3 (Caspase-3)IBA
01/2019 - 11/2011
3Bortezomib (Velcade)FDA Link
12/2018 - 06/2015
3ParaffinIBA
01/2018 - 07/2013
3Long Noncoding RNAIBA
01/2018 - 06/2015
3Gefitinib (Iressa)FDA Link
05/2017 - 01/2016
3idelalisibIBA
12/2015 - 10/2014
3EnzymesIBA
12/2014 - 05/2004
33' Untranslated Regions (3' UTR)IBA
01/2013 - 12/2006
3Saline SolutionIBA
10/2011 - 03/2006
3Lymphotoxin-alpha (Lymphotoxin)IBA
07/2009 - 05/2004
3Dystroglycans (Dystroglycan)IBA
02/2004 - 03/2003
2Dextran SulfateIBA
03/2022 - 04/2020
2sesamolIBA
03/2022 - 09/2020
2Volatile Fatty AcidsIBA
11/2021 - 04/2020

Therapy/Procedure

42Therapeutics
10/2022 - 11/2005
17Radiotherapy
03/2022 - 02/2012
12Drug Therapy (Chemotherapy)
04/2022 - 02/2012
5Immunotherapy
03/2022 - 12/2012
5Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
12/2018 - 01/2015
4Photothermal Therapy
01/2021 - 01/2017
4Chemoradiotherapy
11/2020 - 09/2013
4Aftercare (After-Treatment)
10/2019 - 10/2015
3Hematopoietic Stem Cell Transplantation
12/2018 - 10/2018